Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4FRONT-2 phase 3 trial of single intravitreal 4D-150 versus aflibercept in neovascular age-related macular degeneration
2025-521349-25-00Phase 3Authorised
- Sponsor
- 4D Molecular Therapeutics
- Start
- Dec 2025
- Modality
- Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of 4D-150 in exudative macular degeneration (2 arms), sponsored by 4D Molecular Therapeutics. Primary endpoint: Mean change from baseline in BCVA ETDRS letter score at Week 52. Planned start Dec 2025; status: authorised.
02
Drugs
4D-150
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2025-521349-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521349-25-00.